This episode explores the reality that cancer can sometimes be missed, even when patients and physicians do everything correctly.

Dr. Keisha Davis explains how biology, test limitations, and sampling variability contribute to this outcome from a pathology perspective.

Topics Covered in This Episode

Why cancer can be missed even with appropriate screening Tumor biology and aggressive cancers Location and subtle lesion detection challenges Limits of screening tests Sampling error and tumor heterogeneity Importance of follow-up

Key Takeaways

Screening reduces risk but does not eliminate it Some cancers grow faster than expected Not all cancers are easily detectable Biopsy is a sample, not the full tumor Follow-up is critical

Resources

College of American Pathologists (CAP) American Society for Clinical Pathology (ASCP) Pathology Outlines Mayo Clinic Laboratories

Learn More

The Medical Collective Website https://www.medical-collective.net

Subscribe to the Medical Collective Weekly Newsletter https://substack.com/@themedicalcollective?r=5b2k7j&utm_medium=ios&utm_source=profile&shareImageVariant=blur

Recommended Episode

What Doctors Really Mean by 'Normal Results'